Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of specialty endocrine disorders in neuroendocrinology, reproductive medicine, and women's health. Its pioneering small molecule somatostatin agonist program for the treatment of acromegaly and neuroendocrine tumors aims to provide a convenient, more effective oral therapy for patients whose only current options are painful injected depot drugs. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development to create important new therapeutic options for endocrinologists and their patients.

Key Contact